Douglas S. Sommerville joins Therma Bright advisory board in Toronto

Therma Bright Inc. has announced the appointment of Douglas S. Sommerville to its Advisory Board as of September 12, 2024. With over 30 years of experience in the medical device industry, Sommerville's expertise is expected to significantly enhance the company's business development efforts, particularly for its Venowave product. Previously, he held key positions at Teva Canada Limited and Baxter Healthcare International, where he managed substantial operations and sales. His extensive network within the medical retail and hospital management sectors will be instrumental in promoting Therma Bright's innovative technologies. Sommerville's background includes serving as the Head of Country for Teva Canada, overseeing a subsidiary with sales exceeding $1.3 billion. His role as Global Vice President at Baxter involved managing global sales and marketing for infusion systems, showcasing his capability in driving business growth. Additionally, he has held leadership positions in industry associations, further solidifying his reputation in the pharmaceutical and medical device sectors. The company also announced the granting of incentive stock options to directors, officers, and consultants, allowing them to purchase up to 3,300,000 common shares at a price of $0.08 per share. This move aligns with Therma Bright's strategy to incentivize key personnel and support its growth initiatives. Overall, the addition of Sommerville to the Advisory Board is seen as a strategic move to leverage his expertise and connections, aiming to boost sales and expand the reach of Therma Bright's medical technologies in the market.